Figure 3.
Figure 3. Plasma from SCD patients in steady state and crisis upregulates the NLRP3 inflammasome in platelets from healthy subjects. (A) PPP from SCD patients in steady state (SS) upregulates platelet caspase-1 activity compared with PPP from healthy controls. (B) Platelet caspase-1 activation is further elevated upon incubation with PPP from SCD patients in crisis compared with PPP from the same patients in SS. (C) An NLRP3 inhibitor (MCC950) inhibits caspase-1 activity of platelets in the presence of PPP from healthy subjects and SCD patients in SS and crisis. Data are shown as median with IQR and minimum and maximum values (A,C) and before-after plot (B). The P values were calculated using the Mann-Whitney U test (A), the Wilcoxon signed-rank test (B), and the Friedman test with Dunn multiple comparisons (C). **P < .01, ***P < .001.

Plasma from SCD patients in steady state and crisis upregulates the NLRP3 inflammasome in platelets from healthy subjects. (A) PPP from SCD patients in steady state (SS) upregulates platelet caspase-1 activity compared with PPP from healthy controls. (B) Platelet caspase-1 activation is further elevated upon incubation with PPP from SCD patients in crisis compared with PPP from the same patients in SS. (C) An NLRP3 inhibitor (MCC950) inhibits caspase-1 activity of platelets in the presence of PPP from healthy subjects and SCD patients in SS and crisis. Data are shown as median with IQR and minimum and maximum values (A,C) and before-after plot (B). The P values were calculated using the Mann-Whitney U test (A), the Wilcoxon signed-rank test (B), and the Friedman test with Dunn multiple comparisons (C). **P < .01, ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal